Porównanie skuteczności terapii skojarzonej 0,5% timololem i 2% dorzolamidem oraz 0,5% timololem i 2% pilokarpiną w leczeniu jaskry pierwotnej otwartego kąta i nadciśnienia ocznego

Purpose
To establish the efficacy and safety of timolol 0,5% / dorzolamide 2% fixed combination versus timolol 0,5% / pilocarpine 2% fixed combination, each given twice daily, in primary open-angle glaucoma and ocular hypertensive patients.

Material and methods
In this prospective, multicentred, double-masked trial, 37 patients were treated twice daily with timolol for 4 weeks. Then, they were randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before placed on the opposite treatment medication for 6 weeks.

Results
A total of 36 patients completed the trial. The mean baseline intraocular pressure (IOP) was 22,3± 3,7 mmHg. Following 6 weeks of treatment, the mean decrease of IOP was 18,0± 2,2 mmHg for timolol / dorzolamide combination and 17,4± 2,0 for timolol / pilocarpine combination. The mean diurnal curve IOP was 18,1± 2,2 mmHg for timolol / dorzolamide group and 16,7 ± 1,9 mmHg for timolol / pilocarpine group. These differences were statistically significant. Statistically more patients reported ocular pain and diminished vision during use of the timolol / pilocarpine combination.

Conclusions
This study suggest that timolol 0,5% / pilocarpine 2% fixed combination can provide at least similar efficacious reduction in IOP as timolol 0,5 % / dorzolamide 2% fixed combination in patients with primary open-angle glaucoma and ocular hypertension.